Early on in the pandemic, convalescent blood plasma — from people who have recovered from COVID-19 — was considered a potential game-changer in the treatment of the disease. But since last spring, studies have shown mixed results on just how effective the treatment is. Now, a new study from Hackensack Meridian Health finds when there’s a high enough level of antibodies in the blood, it’s not only safe, but also highly effective at treating the disease, especially when given early on in infection. What’s more, it could protect against the rising variants.
Dr. David Perlin, chief scientific officer with the Hackensack Meridian Center for Discovery and Innovation, explains these findings.